Comparison between Culture Conditions Improving Growth and Differentiation of Blood and Bone Marrow Cells Committed to the Endothelial Cell Lineage

Biological Procedures Online

Claudio Muscari³  Chiara Gamberini¹  Ilaria Basile¹  Francesca Bonafé¹  Simond Valgimigli²  Ombretta Capitani²  Carlo Guarnieri¹  Claudio Marcello Caldarera¹ 

[1] Department of Biochemistry, University of Bologna and National Institute for Cardiovascular Research, Bologna, Italy

[2] Veterinary Clinical Department, University of Bologna, Bologna, Italy

[3] Dipartimento di Biochimica "G. Moruzzi", Universita' di Bologna, Via Irnerio 48, 40126, Bologna, Italy

关键词: Physiologic Neovascularization;    Mesenchymal Stem Cells;    Cell Survival;    Cell Proliferation;    Bone Marrow Cells;    Blood Cells;   

Others  :  797134
DOI  :  10.1007/s12575-009-9023-y

 received in 2009-09-03, accepted in 2009-11-07,  发布年份 2010

【 摘 要 】

The aim of this study was to compare different cell sources and culture conditions to obtain endothelial progenitor cells (EPCs) with predictable antigen pattern, proliferation potential and in vitro vasculogenesis. Pig mononuclear cells were isolated from blood (PBMCs) and bone marrow (BMMCs). Mesenchymal stem cells (MSCs) were also derived from pig bone marrow. Cells were cultured on fibronectin in the presence of a high concentration of VEGF and low IGF-1 and FGF-2 levels, or on gelatin with a lower amount of VEGF and higher IGF-1 and FGF-2 concentrations. Endothelial commitment was relieved in almost all PBMCs and BMMCs irrespective of the protocol used, whilst MSCs did not express a reliable pattern of EPC markers under these conditions. BMMCs were more prone to expand on gelatin and showed a better viability than PBMCs. Moreover, about 90% of the BMMCs pre-cultured on gelatin could adhere to a hyaluronan-based scaffold and proliferate on it up to 3 days. Pre-treatment of BMMCs on fibronectin generated well-shaped tubular structures on Matrigel, whilst BMMCs exposed to the gelatin culture condition were less prone to form vessel-like structures. MSCs formed rough tubule-like structures, irrespective of the differentiating condition used. In a relative short time, pig BMMCs could be expanded on gelatin better than PBMCs, in the presence of a low amount of VEGF. BMMCs could better specialize for capillary formation in the presence of fibronectin and an elevated concentration of VEGF, whilst pig MSCs anyway showed a limited capability to differentiate into the endothelial cell lineage.

【 授权许可】

   
2010 Muscari et al; licensee Springer

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Marsboom G, Janssens S: Endothelial progenitor cells: new perspectives and applications in cardiovascular therapies. Expert Rev Cardiovasc Ther 2008, 6:687-701.
• [2]Yamahara K, Itoh H: Potential use of endothelial progenitor cells for regeneration of the vasculature. Ther Adv Cardiovasc Dis 2009, 3:17-27.
• [3]Boyer M, Townsend LE, Vogel LM, Falk J, Reitz-Vick D, Trevor KT, et al.: Isolation of endothelial cells and their progenitor cells from human peripheral blood. J Vasc Surg 2000, 31(1 Pt 1):181-189.
• [4]Murayama T, Asahara T: Bone marrow-derived endothelial progenitor cells for vascular regeneration. Curr Opin Mol Ther 2002, 4:395-402.
• [5]Hristov M, Erl W, Weber PC: Endothelial progenitor cells. Isolation and characterization. Trends Cardiovasc Med 2003, 13:201-206.
• [6]Urbich C, Dimmeler S: Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004, 95:343-353.
• [7]Park C, Ma YD, Choi K: Evidence for the hemangioblast. Exp Hematol 2005, 33:965-970.
• [8]Hirschi KK, Ingram DA, Yoder MC: Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008, 28:1584-1595.
• [9]Fernandez Pujol B, Lucibello FC, Gehling UM, Lindemann K, Weidner N, Zuzarte ML, et al.: Endothelial-like cells derived from human CD14 positive monocytes. Differentiation 2000, 65:287-300.
• [10]Rehman J, Li J, Orschell CM, March KL: Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003, 107:1164-1169.
• [11]Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, et al.: Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004, 24:288-293.
• [12]Yoon CH, Hur J, Park KW, Kim JH, Lee CS, Oh IY, Kim , et al.: Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells. Circulation 2005, 112:1618-1627.
• [13]Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Amano K, Iba O, et al.: Improvement of collateral perfusion and regional function by implantation of peripheral blood mononuclear cells into ischemic hibernating myocardium. Arterioscler Thromb Vasc Biol 2002, 22:1804-1810.
• [14]Caplan AI: Why are MSCs therapeutic? New data: new insight. J Pathol 2009, 217:318-324.
• [15]Oswald J, Boxberger S, Jørgensen B, Feldmann S, Ehninger G, Bornhäuser M, et al.: Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004, 22:377-384.
• [16]Sieveking DP, Ng MK: Cell therapies for therapeutic angiogenesis: back to the bench. Vasc Med 2009, 14:153-166.
• [17]Douglas WR: Of pigs and men and research: a review of applications and analogies of the pig, sus scrofa, in human medical research. Space Life Sci 1972, 3:226-234.
• [18]Allen J, Khan S, Serrano MC, Ameer G: Characterization of porcine circulating progenitor cells: toward a functional endothelium. Tissue Eng 2008, 14:183-194.
• [19]Mieno S, Clements RT, Boodhwani M, Sodha NR, Ramlawi B, Bianchi C, et al.: Characteristics and function of cryopreserved bone marrow-derived endothelial progenitor cells. Ann Thorac Surg 2008, 85:1361-1366.
• [20]Muscari C, Bonafe' F, Farruggia G, Stanic I, Gamberini C, Carboni M, et al.: Long-term treatment with N-acetylcysteine, but not caloric restriction, protects mesenchymal stem cells of aged rats against tumor necrosis factor-induced death. Exp Gerontol 2006, 41:800-804.
• [21]Pasquinelli G, Orrico C, Foroni L, Bonafè F, Carboni M, Guarnieri C, et al.: Mesenchymal stem cell interaction with a non-woven hyaluronan-based scaffold suitable for tissue repair. J Anat 2009, 213:520-530.
• [22]Ruel M, Wu GF, Khan TA, Voisine P, Bianchi C, Li J, et al.: Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model. Circulation 2003, 108(Suppl 1):II335-II340.
• [23]Pasquinelli G, Vinci MC, Gamberini C, Orrico C, Foroni L, Guarnieri C, et al.: Architectural organization and functional features of early endothelial progenitor cells cultured in a hyaluronan-based polymer scaffold. Tissue Eng Part A 2009, 15:2751-2762.
• [24]He T, Peterson ET, Katusic ZS: Paracrine mitogenic effect of human endothelial progenitor cells: role of interleukin-8. Am J Physiol Heart Circ Physiol 2005, 289:H968-H972.
• [25]Rho GJ, Kumar BM, Balasubramanian SS: Porcine mesenchymal stem cells–current technological status and future perspective. Front Biosci 2009, 14:3942-3961.
• [26]Wang X, Hu Q, Mansoor A, Lee J, Wang Z, Lee T, et al.: Bioenergetic and functional consequences of stem cell-based VEGF delivery in pressure-overloaded swine hearts. Am J Physiol Heart Circ Physiol 2006, 290:H1393-H1405.
• [27]Mertsching H, Walles T, Hofmann M, Schanz J, Knapp WH: Engineering of a vascularized scaffold for artificial tissue and organ generation. Biomaterials 2005, 26:6610-6617.
• [28]Michel JB: Anoikis in the cardiovascular system: known and unknown extracellular mediators. Arterioscler Thromb Vasc Biol 2003, 23:2146-2154.
• [29]Almeida EA, Ilić D, Han Q, Hauck CR, Jin F, Kawakatsu H, et al.: Matrix survival signaling: from fibronectin via focal adhesion kinase to c-Jun NH(2)-terminal kinase. J Cell Biol 2000, 149:741-754.
• [30]Maurice S, Srouji S, Livne E: Isolation of progenitor cells from cord blood using adhesion matrices. Cytotechnology 2007, 54:121-133.
• [31]Prasad Chennazhy K, Krishnan LK: Effect of passage number and matrix characteristics on differentiation of endothelial cells cultured for tissue engineering. Biomaterials 2005, 26:5658-5667.
• [32]Fujio Y, Walsh K: Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 1999, 274:16349-16354.
• [33]Chen CH, Poucher SM, Lu J, Henry PD: Fibroblast growth factor 2: from laboratory evidence to clinical application. Curr Vasc Pharmacol 2004, 2:33-43.
• [34]Kurmasheva RT, Houghton PJ: IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 2006, 1766:1-22.
• [35]Honold J, Lehmann R, Heeschen C, Walter DH, Assmus B, Sasaki K, et al.: Effects of granulocyte colony simulating factor on functional activities of endothelial progenitor cells in patients with chronic ischemic heart disease. Arterioscler Thromb Vasc Biol 2006, 26:2238-2243.
• [36]Jiang D, Liang J, Noble PW: Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 2007, 23:435-461.
• [37]Stern R, Asari AA, Sugahara KN: Hyaluronan fragments: an information-rich system. Eur J Cell Biol 2006, 85:699-715.
• [38]Serrano MC, Pagani R, Ameer GA, Vallet-Regí M, Portolés MT: Endothelial cells derived from circulating progenitors as an effective source to functional endothelialization of NaOH-treated poly(epsilon-caprolactone) films. J Biomed Mater Res A 2009, 87:964-971.
• [39]Bikfalvi A, Cramer EM, Tenza D, Tobelem G: Phenotypic modulations of human umbilical vein endothelial cells and human dermal fibroblasts using two angiogenic assays. Biol Cell 1991, 72:275-278.
• [40]Koike N, Fukumura D, Gralla O, Au P, Schechner JS, Jain RK: Tissue engineering: creation of long-lasting blood vessels. Nature 2004, 428:138-139.
• [41]Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N: Angiogenesis assays: a critical overview. Clin Chem 2003, 49:32-40.